Brainsway ( (BWAY) ) has shared an announcement.
BrainsWay reported record financial results for the fourth quarter and full year of 2024, with quarterly sales reaching $11.4 million, a 27% increase from the previous year. The company achieved a full-year revenue of $41 million, marking a nearly 30% year-over-year growth. BrainsWay’s operational highlights included significant progress in clinical trials and expanded market presence, notably entering the Canadian market and increasing penetration in East Asia. The company also completed a $20 million strategic equity financing transaction with Valor Equity Partners. Looking ahead, BrainsWay anticipates continued strong growth in 2025, projecting revenues between $49 million and $51 million.
More about Brainsway
BrainsWay is a global leader in advanced noninvasive neurostimulation treatments for mental health disorders. The company is advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) technology.
YTD Price Performance: -4.07%
Average Trading Volume: 65,941
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $176.6M
See more insights into BWAY stock on TipRanks’ Stock Analysis page.